POLYMED NSI Week ended 07 Aug 2026

Weekly Investor Report

Poly Medicure Limited · Healthcare · Medical Instruments & Supplies

Open interactive chart View report data
Latest close 1,694 INR
-0.5% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 14.0% above the Trend Line and sits at 53.4% of its 52-week range. The latest completed week returned -0.5%, after a 1.5% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is expensive relative to peers. The latest news-sentiment score is 54/100.

Setup score 47 out of 100
Latest Close 1,694 INR 7 Aug 2026
1W Return -0.5% latest completed week
4W Return 1.5% short-term follow-through
12W Return 13.0% quarterly tape
Trend Breadth 7.7% 4 of 52 weeks active
Volume Ratio 1.0x vs 13-week average
What is working
  • The trend backdrop is active with a 4-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -0.5% Latest completed week; four-week move 1.5%. Indicator stack 18/70 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 54/100 20 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 14.0% above the Trend Line and sits at 53.4% of its 52-week range. The latest completed week returned -0.5%, after a 1.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.3812-week average 0.22

12-week confirmation

Trend active4/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership6/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.38Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 1.5% over four weeks, 13.0% over 12 weeks, and -12.0% over one year. The current trend has remained active for 4 consecutive weeks.

Performance by holding period

1W-0.5%
4W1.5%
12W13.0%
26W21.9%
52W-12.0%
Active trend streak4 weeks
Active weeks in one year4
Trend breadth7.7%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.08Latest activity-pressure read.
Pressure change10.2%Four-week change in activity pressure.
Leadership2.39Latest relative-leadership reading.
RS change137.0%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is expensive relative to peers.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 94% Model confidence 88%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength2/100Blend of value, momentum, and quality. Underlying universe rank 99; rank 1 is best.
Value7/100Relative valuation strength. Underlying universe rank 94; rank 1 is best.
Quality18/100Profitability and accounting quality. Underlying universe rank 83; rank 1 is best.
Momentum28/100Medium-term price momentum. Underlying universe rank 73; rank 1 is best.
Growth32/100Revenue and earnings growth. Underlying universe rank 69; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework2/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
53.5x
Price divided by trailing earnings.
Price / sales
9.2x
Market value relative to trailing revenue.
EV / EBITDA
31.2x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-0.4%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
59.8%
Gross profit retained from each unit of revenue.
Operating margin
9.1%
Operating profit retained from revenue.
Free-cash-flow margin
-3.3%
Free cash flow generated from revenue.
Return on invested capital
3.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
12.3%
Latest one-year revenue growth.
EPS growth
-2.2%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
0.2%
Cash dividends relative to market value.
Buyback yield
-0.0%
Net share repurchases relative to market value.
Shareholder yield
0.2%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment54/100

Weighted news tone is neutral across 20 relevant articles.

5 positive · 14 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-20.9%Distance below the 52-week high.
13-week volatility6.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher15 of 2611 weeks finished lower.
Best week+9.6%Week of 10 Apr.
Worst week-15.5%Week of 29 May.
Latest week-0.5%Week of 7 Aug.

Shape of recent returns

Strong gains9
Modest gains6
Flat weeks0
Modest losses7
Sharp losses4
Recent vol6.2%13-week weekly-return volatility.
Base vol5.1%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew4.0% / -3.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape44/100

Trend, activity pressure, participation, and risk combine to a 44/100 tape read.

 Indicator analysis54/100

Latest 12-week confirmation: trend 4/12, activity pressure 12/12, relative leadership 6/12.

Activity pressure 0.38; No reversal markers Factors12/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 67; Small Cap Core rank 91 SVQF2/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 1558.5 of 1589 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment54/100

Weighted news tone is neutral across 20 relevant articles.

Poly Medicure to host Nuvama for plant visit on June 25 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 20261,694 INR-0.5%1,486 INR1,881 INR1.082.39467.1KOn
31 Jul 20261,702 INR2.3%1,489 INR1,879 INR1.133.38360.6KOn
24 Jul 20261,664 INR-1.0%1,491 INR1,877 INR1.143.42376.4KOn
17 Jul 20261,680 INR0.7%1,494 INR1,874 INR1.121.65514.2KOn
10 Jul 20261,668 INR-0.6%1,498 INR1,870 INR0.981.01328.5KOff
3 Jul 20261,678 INR1.7%1,506 INR1,867 INR0.790.77300.5KOff
26 Jun 20261,650 INR5.6%1,513 INR1,863 INR0.59-0.520Off
19 Jun 20261,563 INR2.0%1,523 INR1,860 INR0.58-5.99107.6KOff
12 Jun 20261,532 INR7.9%1,533 INR1,857 INR0.63-6.76232.3KOff
5 Jun 20261,420 INR5.2%1,547 INR1,855 INR0.68-13.26260.7KOff
29 May 20261,350 INR-15.5%1,563 INR1,852 INR0.84-18.811.7MOff
22 May 20261,598 INR6.6%1,584 INR1,849 INR0.79-5.42588.9KOff
15 May 20261,499 INR-9.3%1,595 INR1,845 INR0.69-11.71632.5KOff
8 May 20261,652 INR9.3%1,609 INR1,842 INR0.59-5.67810.3KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context